VS-7375 posts 67% six-month progression-free survival in metastatic pancreatic cancer as daraxonrasib comparison sharpens

Verastem reported early data for its KRAS-targeted drug VS-7375 in metastatic pancreatic ductal adenocarcinoma: among 22 evaluable patients at 900 mg once daily, 16 remained on treatment at month 6, 6-month progression-free survival was 67% and overall survival 80%. Confirmed objective response rate was 41% (9/22), including 50% (4/8) in second-line patients. The numbers invite comparison with Revolution Medicines' daraxonrasib (RMC-6236), approved as RASONQUE on August 26, 2026, after FDA-disclosed data showed weak performance in a large subgroup that VS-7375's population resembles.